JustWire.io

Wed, 05.08.2026

SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the pricing of its upsized initial public offering of 17,000,000 shares of its common...

Newsfeed

Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026

Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection

Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy

Mobia Medical Announces Vivistim® Procedure Remains Assigned to New Technology APC 1580 under CMS Proposed 2027 Hospital Outpatient Prospective Payment System Rule

ITG, Inc. Announces Pricing of Initial Public Offering

Blockfusion and Blue Acquisition Corp. Announce LOIs for Anchor Lease with a Leading AI Customer and $175 Million Convertible Note Financing and Non-Redemption Agreement, and Advancement of Planned Expansion of Niagara Falls Campus

ITG, Inc. Announces Launch of Initial Public Offering

Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026

Cerebras Systems Announces Closing of Initial Public Offering

Cerebras Systems Announces Pricing of Initial Public Offering

Prospectus for Octave Intelligence plc published and registration statement effective

Avalyn Announces Pricing of Upsized Initial Public Offering

Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

Kailera Therapeutics Announces Pricing of Initial Public Offering

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026

Fervo Energy Expands Board of Directors, Adding Four Directors with Deep Expertise in Energy, Finance, Engineering, and Governance

Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference

Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors

HMH Holding Inc. Announces Pricing of Initial Public Offering

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis

HMH Holding Inc. Announces Launch of Initial Public Offering

ReserveOne Announces Filing of Second Amendment to Registration Statement on Form S-4 with the SEC for Proposed Business Combination with M3-Brigade Acquisition V Corp.

Eagle Nuclear Energy Corp. Commences Trading on Nasdaq Under Ticker Symbol “NUCL”

Eagle Energy Metals and Spring Valley Acquisition Corp. II Announce Closing of Business Combination

ReserveOne Announces Filing of Amendment to Registration Statement on Form S-4 with the SEC for Proposed Business Combination with M3-Brigade Acquisition V Corp.

SOLV Energy Announces Pricing of Initial Public Offering

Eagle Energy Metals Corp. and Spring Valley Acquisition Corp. II Announce Effectiveness of Registration Statement and Record and Meeting Dates for Extraordinary General Meeting of Shareholders to Approve Proposed Business Combination

SOLV Energy Announces Launch of Initial Public Offering

EquipmentShare Debuts on Nasdaq as “EQPT”, Advancing the Digital Transformation of Construction

EquipmentShare Prices Initial Public Offering

Stewards Inc. to Present at the 2026 Sequire Investor Summit in Puerto Rico

Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences

EquipmentShare Marks 10 Years of the OWN Program with $454 Million ABS Transaction

Wealthfront Announces Pricing of Initial Public Offering

Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates

Wealthfront Announces Launch of Initial Public Offering

Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025

Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025

BillionToOne Announces Pricing of Upsized Initial Public Offering

Vivoryon Therapeutics N.V. to Present at Upcoming Conferences

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BillionToOne Announces Launch of Initial Public Offering Roadshow

MapLight Therapeutics Announces Pricing of Initial Public Offering

Central Bancompany, Inc. Files Registration Statement for Proposed Initial Public Offering